NEAUVIA


INTENSE RHEOLOGY

Intense Rheology is a biodegradable Hyaluronic Acid hydrogel crosslinked with PEG. It is resorbed over time and intended to restore lost volume of the soft tissue.¹



- Crosslinking: PEG
- ** *HA concentration:* 22 mg/ml
- Contains: Glycine and L-Proline
- **Extrusion Force:** Medium
- Syringe: 1x1ml
- extstyle ext
- Duration: 6 months degradation average time¹
- Area of injection: Face
- Injection plane: Intradermal and/or subcutis

1. Data on file.





Discover Smart Combination Therapy: Nlift mid-face synergistic protocol.





INTENSE RHEOLOGY

and its unique composition

innovative and advanced technology that combines Hyaluronic Acid and PEGDE in one network. Intense Rheology is enriched with Glycine and L-Proline.

PIONEER with PEG

PEG is a well-known polymer in the pharmaceutical market, due to its uniqueness, versatility and safety profile.^{1,2} **Neauvia chose PEG**, as a crosslinker, differentiating itself in the market and presenting the following main features:

HIGH-SAFETY PROFILE:

- 1 No pathologic inflammatory reactions*3
- 2 No citotoxicity activity detected⁴
- 3 No crosslinker residuals remain and no changes in the surrounding tissues can be observed after complete degradation³
- 4 Reversible filling^{3,5}

DISTINCTIVE CHARACTERISTICS:

- 1 Mechanical properties that mimic those of natural skin tissues^{1,6}
- 2 High cohesivity and balanced viscoelasticity^{3,7}
- 3 High resistance to heat and high thermodynamic **stability**⁶ to allow combined protocols
- 4 Temporary filling decreasing at 6 months³

GLYCINE and L-PROLINE

Neauvia's fillers are enriched with Glycine and L-Proline, which are proteinogenic amino acids used in the biosynthesis of proteins3. They are added to the phosphate buffer solution to tune the rheological properties (viscoelastic properties) and the swelling resistance³. They ensure in Neauvia's fillers formulation a better control of the hydrogel swelling capacity in the postimplant phase.8

- Lee KH, Choi B, Kim ES, Kang JH, Kim EK and Han SG. In vitro toxicity assessment of crosslinking agents used in Hyaluronic Acid dermal filler. Toxicology in Vitro, Volume 70, 2020 105034
- ata on file.

 N, Lotti T, Monticelli D, Rauso R, González-Isaza P, D'Este E, Calligaro A, Sommatis S, Maccario C, Mocchi R, Lotti J, Wollina U, Tchernev G and França K. In vitro evaluation of the biosafety of Hyaluronic Acid PEG cross-linked omolecules of Calcium Hydroxyapatite in low concentration. Open Access Maced J Med Sci. https://doi.org/10.3889/oarnjms.2018.044

 N, Lotti T, Monticelli D, Martina V, Cipolia G, D'Este E, Calligaro A, Mocchi R, Maccario C, Sommatis S, Lotti J, Wollina U, Tchernev G and França K. In vitro evaluation of the sensitivity of a Hyaluronic Acid PEG cross-linked